← All trials
NCT04800692
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Feb 28, 2023
- First posted
- Mar 16, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MassachusettsLead sponsor
- University of MassachusettsOverall official - principal investigator
- University of MassachusettsReponsible party - principal investigator
- National Institute on Aging (NIA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.